Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575075 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of RR-HNK in OCD
A Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Carolyn Rodriguez.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06575075 is a Phase 1 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Carolyn Rodriguez. The registered enrollment target is 45 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06575075, a Phase 1 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Carolyn Rodriguez.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RR-HNK/Hydroxynorketamine
Study Locations (1)
California
- Stanford University School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-01-23 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06575075
The ClinicalTrials.gov registry entry for NCT06575075 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Carolyn Rodriguez, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06575075 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06575075 about?
NCT06575075 is a clinical study titled "Pilot Study of RR-HNK in OCD". The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
What is the current status of trial NCT06575075?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2026-01-23. Estimated completion is 2029-11-30.
What conditions does trial NCT06575075 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT06575075?
The interventions under investigation include: Placebo (DRUG), RR-HNK/Hydroxynorketamine (DRUG).
Who is sponsoring clinical trial NCT06575075?
This trial is sponsored by Carolyn Rodriguez, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06575075 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
RECRUITING · Phase 1
-
Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
RECRUITING · Phase 1
-
Effects of Repeated Psilocybin Dosing in OCD
ACTIVE NOT RECRUITING · Phase 1
-
Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder
COMPLETED · Phase 1
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.